Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05838742




Registration number
NCT05838742
Ethics application status
Date submitted
20/04/2023
Date registered
3/05/2023
Date last updated
19/09/2024

Titles & IDs
Public title
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis Pain
Scientific title
A Multicentre Randomized, Double-blind, Placebo Controlled, Dose-finding, Phase 2 Study (MARS-17) of GSK3858279 in Adult Participants With Moderate to Severe Pain Due to Knee Osteoarthritis
Secondary ID [1] 0 0
2022-502799-22-00
Secondary ID [2] 0 0
209978
Universal Trial Number (UTN)
Trial acronym
MARS-17
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain 0 0
Osteoarthritis, Knee 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK3858279
Treatment: Drugs - Placebo

Experimental: GSK3858279 Dose 1 - Participants will receive GSK3858279 dose 1.

Experimental: GSK3858279 Dose 2 - Participants will receive GSK3858279 dose 2.

Experimental: GSK3858279 Dose 3 - Participants will receive GSK3858279 dose 3.

Experimental: GSK3858279 Dose 4 - Participants will receive GSK3858279 dose 4.

Placebo comparator: Placebo - Participants will receive placebo.


Treatment: Drugs: GSK3858279
GSK3858279 will be administered.

Treatment: Drugs: Placebo
Placebo will be administered.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline at Week 12 in weekly average of average daily knee pain intensity, assessed on the Numeric Rating Scale (NRS)
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [1] 0 0
Change from baseline at Week 12 in Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [2] 0 0
Change from baseline at Week 12 in WOMAC function subscale score
Timepoint [2] 0 0
Baseline and Week 12
Secondary outcome [3] 0 0
Change from baseline at Week 12 in patient global assessment of disease (PtGA)
Timepoint [3] 0 0
Baseline and Week 12
Secondary outcome [4] 0 0
Occurrence of adverse events (AEs), serious AE (SAEs) and AEs of special interest (AESI)
Timepoint [4] 0 0
Up to 31 weeks
Secondary outcome [5] 0 0
Change from Baseline in Haematology Parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils, white blood cell (WBC), and platelet count (Giga cells per liter)
Timepoint [5] 0 0
Baseline and up to Week 31
Secondary outcome [6] 0 0
Change from Baseline in Haematology Parameters: Red blood cell (RBC) count, (Trillion cells per liter)
Timepoint [6] 0 0
Baseline and up to Week 31
Secondary outcome [7] 0 0
Change from baseline in haematology parameter: Haemoglobin (Hb) (Grams per liter)
Timepoint [7] 0 0
Baseline and up to Week 31
Secondary outcome [8] 0 0
Change from baseline in haematology parameter: Haematocrit (Proportion of red blood cells in blood)
Timepoint [8] 0 0
Baseline and up to Week 31
Secondary outcome [9] 0 0
Change from baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), Gamma-glutamyl transferase (GGT), and Alkaline Phosphatase (AP) (International units per liter)
Timepoint [9] 0 0
Baseline and up to Week 31
Secondary outcome [10] 0 0
Change from baseline in clinical chemistry parameter: Total bilirubin (Micromoles per liter)
Timepoint [10] 0 0
Baseline and up to Week 31
Secondary outcome [11] 0 0
Number of participants with greater than or equal to (=) grade 3 hematological/clinical chemistry abnormalities according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE)
Timepoint [11] 0 0
Up to 31 weeks
Secondary outcome [12] 0 0
Population parameters for the model describing the relationship between Dose, PK and response assessed on the NRS
Timepoint [12] 0 0
At Week 12
Secondary outcome [13] 0 0
Maximum observed concentration (Cmax) of GSK3858279
Timepoint [13] 0 0
At Week 12
Secondary outcome [14] 0 0
The amount of time for GSK3858279 to reach Cmax (tmax)
Timepoint [14] 0 0
At Week 12
Secondary outcome [15] 0 0
Pre-dose (trough) concentration at the end of the dosing interval (Ctau) of GSK3858279
Timepoint [15] 0 0
At Week 12
Secondary outcome [16] 0 0
Average concentration over a dosing interval (Cavg) of GSK3858279
Timepoint [16] 0 0
At Week 12
Secondary outcome [17] 0 0
Area under the time-concentration curve (AUC) over the dosing interval (0-tau) (AUC[0-tau]) of GSK3858279
Timepoint [17] 0 0
At Week 12

Eligibility
Key inclusion criteria
* Participant must be 40 to 80 years of age inclusive
* OA of the index knee as defined by symptomatic for = 6 months with a clinical diagnosis of OA as per American College of Rheumatology (ACR) clinical diagnosis criteria.
* Kellgren and Lawrence (KL) score = 2 on X-ray in the index knee
* An average of the average daily pain score of =4 and less than or equal to (=) 9 by the 11-point NRS (0-10)
* Body mass index (BMI) of < 40 kilogram per meter square (kg/m^2) (inclusive).
* Capable of giving signed informed consent.
Minimum age
40 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History or presence of cardiovascular, renal, gastrointestinal, lymphatic disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments.
* History or current evidence of any inflammatory arthritis such as rheumatoid arthritis, infective arthritis, Paget's disease, osteonecrosis, osteoporotic fracture, or any other joint disease that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of osteoarthritis.
* History of significant trauma or surgery to a knee or hip within the last 6 months.
* Current immunodeficiency diseases including but not limited to acquired immunodeficiency disorder or immunoglobulin deficiency.
* Current or previous active Mycobacterium tuberculosis
* History or evidence of clinically significant multiple or severe drug allergies
* History of malignancy within the last 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
* Alanine transaminase (ALT) >1.5 times upper limit of normal (ULN).
* Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35 percent (%)
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Evidence of renal insufficiency, indicated by estimated creatinine clearance < 60 millilitre/ minute (mL/min)/1.73 m^2 at screening.
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/09/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/11/2024
Actual
Sample size
Target
Accrual to date
Final
263
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
GSK Investigational Site - Botany
Recruitment hospital [2] 0 0
GSK Investigational Site - Camberwell
Recruitment hospital [3] 0 0
GSK Investigational Site - Kotara
Recruitment hospital [4] 0 0
GSK Investigational Site - Sydney
Recruitment postcode(s) [1] 0 0
2019 - Botany
Recruitment postcode(s) [2] 0 0
3124 - Camberwell
Recruitment postcode(s) [3] 0 0
2289 - Kotara
Recruitment postcode(s) [4] 0 0
2010 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Nevada
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Virginia
Country [11] 0 0
Argentina
State/province [11] 0 0
Buenos Aires-San Isidro
Country [12] 0 0
Argentina
State/province [12] 0 0
Ciudad Autonoma Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Ciudad Autonoma de Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Ciudad AutOnoma de Buenos Aire
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autonoma de Buenos Aire
Country [16] 0 0
Argentina
State/province [16] 0 0
Mar del Plata
Country [17] 0 0
Canada
State/province [17] 0 0
Brampton
Country [18] 0 0
Canada
State/province [18] 0 0
Guelph
Country [19] 0 0
Canada
State/province [19] 0 0
Joliette
Country [20] 0 0
Canada
State/province [20] 0 0
Sarnia
Country [21] 0 0
Canada
State/province [21] 0 0
Sherbrooke
Country [22] 0 0
Canada
State/province [22] 0 0
Toronto
Country [23] 0 0
Canada
State/province [23] 0 0
Trois-Rivieres
Country [24] 0 0
Canada
State/province [24] 0 0
Victoria
Country [25] 0 0
Canada
State/province [25] 0 0
Winchester
Country [26] 0 0
China
State/province [26] 0 0
Beijing
Country [27] 0 0
China
State/province [27] 0 0
Changchun
Country [28] 0 0
China
State/province [28] 0 0
Chengdu
Country [29] 0 0
China
State/province [29] 0 0
Guangzhou
Country [30] 0 0
China
State/province [30] 0 0
Huhhot
Country [31] 0 0
China
State/province [31] 0 0
Nanjing
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Shenyang
Country [34] 0 0
China
State/province [34] 0 0
Shijiazhuang
Country [35] 0 0
China
State/province [35] 0 0
Tianjin
Country [36] 0 0
China
State/province [36] 0 0
ZhuZhou
Country [37] 0 0
France
State/province [37] 0 0
Cahors
Country [38] 0 0
France
State/province [38] 0 0
Dax
Country [39] 0 0
France
State/province [39] 0 0
La Roche Sur Yon
Country [40] 0 0
France
State/province [40] 0 0
La Rochelle Cedex 1
Country [41] 0 0
France
State/province [41] 0 0
Montpellier cedex 5
Country [42] 0 0
France
State/province [42] 0 0
Paris
Country [43] 0 0
France
State/province [43] 0 0
Saint-Priest en Jarez
Country [44] 0 0
Germany
State/province [44] 0 0
Berlin
Country [45] 0 0
Germany
State/province [45] 0 0
Hamburg
Country [46] 0 0
Germany
State/province [46] 0 0
Magdeburg
Country [47] 0 0
Germany
State/province [47] 0 0
Rendsburg
Country [48] 0 0
Japan
State/province [48] 0 0
Fukuoka
Country [49] 0 0
Japan
State/province [49] 0 0
Ibaraki
Country [50] 0 0
Japan
State/province [50] 0 0
Nagano
Country [51] 0 0
Japan
State/province [51] 0 0
Osaka
Country [52] 0 0
Japan
State/province [52] 0 0
Saitama
Country [53] 0 0
Japan
State/province [53] 0 0
Shimane
Country [54] 0 0
Japan
State/province [54] 0 0
Tokyo
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Seoul
Country [56] 0 0
Mexico
State/province [56] 0 0
Chihuahua
Country [57] 0 0
Mexico
State/province [57] 0 0
Guadalajara
Country [58] 0 0
Mexico
State/province [58] 0 0
Merida
Country [59] 0 0
Mexico
State/province [59] 0 0
Mexicali
Country [60] 0 0
Mexico
State/province [60] 0 0
Torreon
Country [61] 0 0
South Africa
State/province [61] 0 0
Cape Town
Country [62] 0 0
South Africa
State/province [62] 0 0
Gauteng
Country [63] 0 0
South Africa
State/province [63] 0 0
Johannesburg
Country [64] 0 0
South Africa
State/province [64] 0 0
Stellenbosch
Country [65] 0 0
Spain
State/province [65] 0 0
A Coruna
Country [66] 0 0
Spain
State/province [66] 0 0
Barcelona
Country [67] 0 0
Spain
State/province [67] 0 0
Madrid
Country [68] 0 0
Spain
State/province [68] 0 0
Santander
Country [69] 0 0
Spain
State/province [69] 0 0
Santiago de Compostela
Country [70] 0 0
Spain
State/province [70] 0 0
Sevilla
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Blackpool
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Cannock
Country [73] 0 0
United Kingdom
State/province [73] 0 0
London
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Manchester
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Norwich

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis (OA) pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279.
Trial website
https://clinicaltrials.gov/study/NCT05838742
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05838742